Evidence map›Paper›PMID 40416564›Full record

ArticleActa Cardiologica Sinica2025

Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer.

Wei-Ting Chang, Jiang-Huang Hong, Dong-Yi Chen, Chao-Yuan Huang, Yen-Chou Chen, Tai-Lung Cha, Yen-Wen Wu, Tzu-Ping Lin, Kai-Hung Cheng, Pei-Jhang Chiang and 16 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta Cardiologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Wei-Ting ChangDepartment of Cardiology, Chi Mei Medical Center, Tainan; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung.
Jiang-Huang HongDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei.
Dong-Yi ChenDivision of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan.
Chao-Yuan HuangDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei.
Yen-Chou ChenDivision of Cardiology and Cardiovascular Research Centre, Taipei Medical University Hospital.
Tai-Lung ChaDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei.
Yen-Wen WuDivision of Cardiology, Cardiovascular Medical Center, and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City.
Tzu-Ping LinDepartment of Urology, Taipei Veterans General Hospital, National Yang Ming Chiao Tung University, Taipei.
Kai-Hung ChengKao-Ho Hospital, Kaohsiung.
Pei-Jhang ChiangDivision of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei.
Chung-Lieh HungCardiovascular Division, Department of Internal Medicine, MacKay Memorial Hospital, MacKay Medical College, Taipei.
Shian-Shiang WangDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung.
Wen-Hwa WangDepartment of Cardiology, Kaohsiung Veterans General Hospital, Kaohsiung.
I-Hung ShaoDivision of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan.
Jo-Nan LiaoDivision of Cardiology, Department of Medicine, Taipei Veterans General Hospital; Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University.
Sheng-Chun HungDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung.
Hung-Ju LinCardiovascular Center, Department of Internal Medicine, National Taiwan University Hospital, Taipei.
Shu-Pin HuangDepartment of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung.
Ping-Yen LiuDivision of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University.
Kuan-Hua HuangDepartment of Urology, Chi Mei Medical Center, Tainan.
Tzung-Dau WangCardiovascular Center, Department of Internal Medicine, National Taiwan University Hospital, Taipei.
Jen-Tai LinDivision of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung.
Yi-Heng LiDivision of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University.
Hsi-Chin WuDepartment of Urology, China Medical University Hospital; School of Medicine, China Medical University, Taichung, Taiwan.
Jacob See-Tong PangDivision of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan.
Wen-Jone ChenCardiovascular Center, Department of Internal Medicine, National Taiwan University Hospital, Taipei.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PC) is one of the leading causes of cancer-related deaths among men globally, and it frequently coexists with cardiovascular disease (CVD). With increasing cancer survival rates and an aging population, the incidence of CVD among PC patients is also on the rise. The treatments for PC include androgen deprivation therapy, androgen receptor pathway inhibitors, and docetaxel-based chemotherapy, and the cardiovascular complications include hypertension, metabolic syndrome, heart failure and arrhythmias. As it is important to provide personalized treatment planning and close monitoring, cardio-oncology collaboration plays a crucial role in optimizing treatment outcomes, emphasizing cardiovascular risk assessments and tailored treatment plans that balance cancer control and cardiovascular health. In this consensus statement, we review several important issues including the association between CVD and PC, screening for cardiovascular diseases and risk factors, timing and criteria for cardiology referral, cardiovascular risk assessments and management, and multidisciplinary collaboration and patient education. However, challenges remain in screening and preventive measures, and future research should focus on developing robust cardiovascular risk assessment tools, preventive measures, and interdisciplinary approaches to improve patient outcomes and reduce cardiovascular morbidity in patients being treated for PC.

Indexed as

Androgen deprivation therapyAndrogen receptor pathway inhibitorsCardio-oncologyCardiovascular diseaseProstate cancer

Identifiers

PMID40416564
PMCPMC12099247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.